Literature DB >> 16223252

Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry.

Xia Xu1, Timothy D Veenstra, Stephen D Fox, John M Roman, Haleem J Issaq, Roni Falk, Joseph E Saavedra, Larry K Keefer, Regina G Ziegler.   

Abstract

A sensitive, specific, accurate, and precise high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry method for measuring the absolute quantities of 15 endogenous estrogens and their metabolites in human urine has been developed and validated. The method requires a single hydrolysis/extraction/derivatization step and only 0.5 mL of urine, yet is capable of simultaneously quantifying estrone and its 2-, 4-methoxy and 2-, 4-, and 16alpha-hydroxy derivatives, and 2-hydroxyestrone-3-methyl ether; estradiol and its 2-, 4-methoxy and 2-, 16alpha-hydroxy derivatives, 16-epiestriol, 17-epiestriol, and 16-ketoestradiol in pre- and postmenopausal women as well as men. Standard curves are linear over a 10(3)-fold concentration range with the standard error of the estimate (SEE) and the relative standard error of the estimate (RSEE) for the linear regression line ranging from 0.0131 to 0.1760 and 1.2 to 7.3%, respectively. The lower limit of quantitation for each estrogen is 0.02 ng/0.5 mL urine sample (2 pg on column), with the percent recovery of a known added amount of compound (accuracy) of 96-107% and an overall precision, including the hydrolysis, extraction, and derivatization steps, of 1-5% relative standard deviation (RSD) for samples prepared concurrently and 1-12% RSD for samples prepared in separate batches. Since individual patterns of estrogen metabolism may influence the risk of breast cancer, accurate, precise, and specific measurement of endogenous estrogen metabolites in biological matrixes will facilitate future research on breast cancer prevention, screening, and treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223252     DOI: 10.1021/ac050697c

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  70 in total

1.  Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women.

Authors:  A Heather Eliassen; Donna Spiegelman; Xia Xu; Larry K Keefer; Timothy D Veenstra; Robert L Barbieri; Walter C Willett; Susan E Hankinson; Regina G Ziegler
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

2.  Unraveling genes, hormones, and breast cancer.

Authors:  Jonine D Figueroa; Louise A Brinton
Journal:  J Natl Cancer Inst       Date:  2012-04-03       Impact factor: 13.506

Review 3.  Epidemiologic studies of estrogen metabolism and breast cancer.

Authors:  Regina G Ziegler; Barbara J Fuhrman; Steven C Moore; Charles E Matthews
Journal:  Steroids       Date:  2015-02-26       Impact factor: 2.668

4.  Comparability of serum, plasma, and urinary estrogen and estrogen metabolite measurements by sex and menopausal status.

Authors:  Sally B Coburn; Frank Z Stanczyk; Roni T Falk; Katherine A McGlynn; Louise A Brinton; Joshua Sampson; Gary Bradwin; Xia Xu; Britton Trabert
Journal:  Cancer Causes Control       Date:  2018-12-01       Impact factor: 2.506

5.  Estrogen Metabolism in Premenopausal Women Is Related to Early Life Body Fatness.

Authors:  A Heather Eliassen; Regina G Ziegler; Lauren C Houghton; Julia S Sisti; Susan E Hankinson; Jing Xie; Xia Xu; Robert N Hoover
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-06       Impact factor: 4.254

Review 6.  Analysis of estrogens and androgens in postmenopausal serum and plasma by liquid chromatography-mass spectrometry.

Authors:  Qingqing Wang; Lisa Bottalico; Clementina Mesaros; Ian A Blair
Journal:  Steroids       Date:  2014-08-20       Impact factor: 2.668

Review 7.  Estrogens in the breast tissue: a systematic review.

Authors:  Lusine Yaghjyan; Graham A Colditz
Journal:  Cancer Causes Control       Date:  2011-02-01       Impact factor: 2.506

8.  A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.

Authors:  Cynthia A Thomson; H H Sherry Chow; Betsy C Wertheim; Denise J Roe; Alison Stopeck; Gertraud Maskarinec; Maria Altbach; Pavani Chalasani; Chuan Huang; Meghan B Strom; Jean-Philippe Galons; Patricia A Thompson
Journal:  Breast Cancer Res Treat       Date:  2017-05-30       Impact factor: 4.872

9.  Effect of tumor necrosis factor-alpha on estrogen metabolism and endometrial cells: potential physiological and pathological relevance.

Authors:  Salama A Salama; Marwa W Kamel; Concepcion R Diaz-Arrastia; Xia Xu; Timothy D Veenstra; Sana Salih; Shaleen K Botting; Raj Kumar
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

10.  Liquid chromatography-mass spectrometry (LC-MS) of steroid hormone metabolites and its applications.

Authors:  Trevor M Penning; Seon-Hwa Lee; Yi Jin; Alejandro Gutierrez; Ian A Blair
Journal:  J Steroid Biochem Mol Biol       Date:  2010-01-18       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.